James Wassil

579 total citations
13 papers, 441 citations indexed

About

James Wassil is a scholar working on Epidemiology, Microbiology and Infectious Diseases. According to data from OpenAlex, James Wassil has authored 13 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 8 papers in Microbiology and 1 paper in Infectious Diseases. Recurrent topics in James Wassil's work include Pneumonia and Respiratory Infections (11 papers), Bacterial Infections and Vaccines (8 papers) and Respiratory viral infections research (5 papers). James Wassil is often cited by papers focused on Pneumonia and Respiratory Infections (11 papers), Bacterial Infections and Vaccines (8 papers) and Respiratory viral infections research (5 papers). James Wassil collaborates with scholars based in United States, Chile and United Kingdom. James Wassil's co-authors include Maria Stella, Duccio Medini, Peter Dull, Daniela Toneatto, Jeffrey J. Stoddard, Miguel O’Ryan, E. David G. McIntosh, Michael Bröker, Jo Anne Welsch and Ray Borrow and has published in prestigious journals such as The Lancet Infectious Diseases, Drugs and Vaccine.

In The Last Decade

James Wassil

13 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Wassil United States	9	308	306	55	43	34	13	441
Jeannette N. Williams United Kingdom	12	334 1.1×	259 0.8×	88 1.6×	54 1.3×	29 0.9×	16	424
Jennifer L. Reimche United States	11	185 0.6×	146 0.5×	90 1.6×	49 1.1×	24 0.7×	13	389
Marisol Figueira United States	11	134 0.4×	180 0.6×	63 1.1×	38 0.9×	20 0.6×	17	321
Yanina Lamberti Argentina	12	303 1.0×	216 0.7×	76 1.4×	50 1.2×	94 2.8×	23	388
Sara Marchi Italy	10	155 0.5×	133 0.4×	102 1.9×	107 2.5×	29 0.9×	15	301
Machao Li China	12	148 0.5×	254 0.8×	86 1.6×	115 2.7×	44 1.3×	29	369
Cecilia Fazio Italy	16	569 1.8×	515 1.7×	61 1.1×	50 1.2×	24 0.7×	52	676
Mary Matheson United Kingdom	12	434 1.4×	401 1.3×	68 1.2×	85 2.0×	35 1.0×	18	550
Kyungcheol Yi United States	10	182 0.6×	127 0.4×	79 1.4×	21 0.5×	29 0.9×	10	352
Serena Giuntini United States	16	368 1.2×	300 1.0×	52 0.9×	75 1.7×	55 1.6×	20	471

Countries citing papers authored by James Wassil

Since Specialization

Citations

This map shows the geographic impact of James Wassil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Wassil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Wassil more than expected).

Fields of papers citing papers by James Wassil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Wassil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Wassil. The network helps show where James Wassil may publish in the future.

Co-authorship network of co-authors of James Wassil

This figure shows the co-authorship network connecting the top 25 collaborators of James Wassil. A scholar is included among the top collaborators of James Wassil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Wassil. James Wassil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Wassil, James, Massimo Sisti, Jeff Fairman, et al.. (2024). A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older. Vaccine. 42(25). 126124–126124. 6 indexed citations

Wassil, James, Jeff Fairman, Matthew Davis, et al.. (2023). Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial. The Lancet Infectious Diseases. 24(3). 308–318. 18 indexed citations

Fairman, Jeff, Paresh Agarwal, Peter Davey, et al.. (2021). 1047. Development of a Next Generation 30+ Valent Pneumococcal Conjugate Vaccine (VAX-XP) Using Site-Specific Carrier Protein Conjugation. Open Forum Infectious Diseases. 8(Supplement_1). S615–S615. 3 indexed citations

Fairman, Jeff, Paresh Agarwal, Peter Davey, et al.. (2021). Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23). Vaccine. 39(23). 3197–3206. 34 indexed citations

Jansen, Kathrin U., William C. Gruber, Raphael Simon, James Wassil, & Annaliesa S. Anderson. (2021). The impact of human vaccines on bacterial antimicrobial resistance. A review. Environmental Chemistry Letters. 19(6). 4031–4062. 44 indexed citations

McIntosh, E. David G., Michael Bröker, James Wassil, Jo Anne Welsch, & Ray Borrow. (2015). Serum bactericidal antibody assays – The role of complement in infection and immunity. Vaccine. 33(36). 4414–4421. 66 indexed citations

Nolan, Terry, et al.. (2015). Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. Vaccine. 33(36). 4437–4445. 19 indexed citations

Medini, Duccio, Maria Stella, & James Wassil. (2015). MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 33(23). 2629–2636. 93 indexed citations

McIntosh, E. David G., et al.. (2014). Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals—the example of serogroup B meningococcal infection. PubMed. 3(1). 13–23. 9 indexed citations

10.

Huels, Jasper, et al.. (2013). Modelled evaluation of multi-component meningococcal vaccine (Bexsero^®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK. Epidemiology and Infection. 142(9). 2000–2012. 12 indexed citations

11.

O’Ryan, Miguel, Jeffrey J. Stoddard, Daniela Toneatto, James Wassil, & Peter Dull. (2013). A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program. Drugs. 74(1). 15–30. 128 indexed citations

12.

Wassil, James, E. David G. McIntosh, Davide Serruto, et al.. (2012). The early clinical development of a multicomponent vaccine against meningococcal serogroup B. Clinical Investigation. 2(5). 503–517. 5 indexed citations

13.

Pizza, Mariagrazia, Lisa DeTora, & James Wassil. (2012). Advances in meningococcal vaccines. Clinical Practice. 9(1). 101–117. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact